Resveratrol may replace aspirin as heart protector
LAS VEGAS Researchers at the University of Connecticut may have found a substitute for aspirin in preventing heart attacks, according to a new study in the form of a compound in red wine.
Red wine’s cardiovascular benefits have been known for a long time, but the researchers found that when inducing heart attacks in animals, administering a molecule known as resveratrol significantly reduced damage to the heart’s muscles, and the animals survived.
“Resveratrol likely fulfills the definition of a pharmacological preconditioning compound and gives hope for the therapeutic promise of alternative medicine,” University of Connecticut School of Medicine researcher Dipak Das said in a statement.
Das found that while doses of 175 to 350 mg of resveratrol reduced damage to the heart, doses 10 times greater increased the area of damage. Meanwhile, the branded resveratrol pill Longevinex, made by Resveratrol Partners of Las Vegas, was found to afford the same level of protection at 100 mg. Still, the Web site for Longevinex says the Food and Drug Administration has not evaluated the pill’s health benefits.
Kerr Drug honored for MTM services
RALEIGH, N.C. Thousands of patient interventions by Kerr Drug pharmacists have earned the chain recognition from a leading pharmaceutical health provider as the nation’s top provider of pharmacy-based medication therapy management.
It’s the third year in a row Kerr has won the honor, bestowed by Outcomes Pharmaceutical Health Care, a national MTM provider network. In bestowing the award, Outcomes noted that Kerr pharmacists served nearly 10,000 MTM-eligible patients in 2008, saving more than $2 million in estimated costs.
“Over the past year, Kerr Drug has remained a front-runner in the provision of MTM services and has clearly demonstrated the value pharmacists deliver to the health care system,” said Outcomes VP Brand Newland.
Outcomes also named the Kerr store in Moncks Corner, S.C., as the top individual pharmacy for 2008 in its eighth region, an operating area that represents Georgia and South Carolina.
New drug application review for Exenatide extended
INDIANAPOLIS A diabetes drug developed by Amylin, Eli Lilly and Alkermes will be reviewed by the Food and Drug Administration March 12.
The revised action date of Exenatide once weekly is the result of the FDA’s decision to allow five additional days for its review of pending regulatory applications following the agency’s recent five-day weather-related closure.
Exenatide once weekly is an investigational, extended-release medication for Type 2 diabetes designed to deliver continuous therapeutic levels of exenatide in a single weekly dose. The NDA for exenatide once weekly was submitted in May 2009 and accepted by the FDA in July 2009.